Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Ra-223 dichloride|DRUG: Denosumab|DRUG: Hormone Therapy
Sponsor: M.D. Anderson Cancer Center
Collaborators: Bayer